This review provides an overview of the current understanding of the role of targeted therapy in NSCLC, delves into the historical processes underlying EGFR-TKI resistance, and explores the potential of utilizing glycolysis inhibitors that are derived from natural products as a strategy for overcoming EGFR-TKI resistance. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.